MedTrace Logo

Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

NCT00331500 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 287

Last updated 2017-08-14

No results posted yet for this study

Summary

The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

DRUG

Olopatadine Hydrochloride Ophthalmic Solution Vehicle

Inactive ingredients used as a placebo comparator

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Alcon, A Novartis Company · Alcon, a Novartis Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-18
Primary Completion
2006-07-27
Completion
2006-07-27

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00331500 on ClinicalTrials.gov